Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Octocrylene, Octinoxate, Octisalate, Titanium Dioxide, Ensulizole
Brand Name
Exel Clarifying Line Daily Fluid Sun Shield White Color Broad Spectrum Spf 60 Plus
Generic Name
Octocrylene, Octinoxate, Octisalate, Titanium Dioxide, Ensulizole
Active Ingredient
EnsulizoleCategory
Adenosine Receptor Agonist [EPC]
Variants
2
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Exel Clarifying Line Daily Fluid Sun Shield White Color Broad Spectrum Spf 60 Plus, you must consult a qualified healthcare professional.
Detailed information about Exel Clarifying Line Daily Fluid Sun Shield White Color Broad Spectrum Spf 60 Plus
Ensulizole is a potent Adenosine Receptor Agonist [EPC] utilized for its modulatory effects on purinergic signaling. It plays a critical role in cardiovascular and neurological management by targeting specific adenosine receptor subtypes to regulate cellular activity and inflammatory responses.
The dosage of Ensulizole must be highly individualized based on the patient's clinical response, the severity of the condition being treated, and the presence of any underlying comorbidities.
Ensulizole is currently not approved for use in pediatric patients under the age of 18. The safety and efficacy of adenosine receptor agonists in children have not been established in large-scale clinical trials. Because the purinergic system undergoes significant development during childhood, the risk of unpredictable cardiovascular or neurological responses is high. If a pediatric use is considered, it must be under the strict guidance of a specialist in a controlled clinical environment.
Since 60% of Ensulizole is excreted via the kidneys, patients with impaired renal function require careful monitoring. For patients with a Creatinine Clearance (CrCl) between 30-60 mL/min, a 25% dose reduction is generally recommended. For those with CrCl below 30 mL/min, Ensulizole should be used with extreme caution, often starting at the lowest possible dose.
In patients with mild to moderate hepatic impairment (Child-Pugh Class A or B), no initial dose adjustment is typically required, but liver enzymes should be monitored periodically. In severe hepatic impairment (Child-Pugh Class C), the metabolism of Ensulizole may be significantly slowed, increasing the risk of systemic toxicity. Dose reductions of 50% may be necessary.
Geriatric patients are often more sensitive to the effects of adenosine agonists. Due to the higher prevalence of underlying conduction system disease (e.g., sinus node dysfunction) and reduced renal clearance in the elderly, healthcare providers usually start at the lowest end of the dosing spectrum (25 mg once or twice daily) and monitor blood pressure and heart rate closely.
To ensure the best results and minimize side effects, follow these administration guidelines:
If you miss a dose of Ensulizole, take it as soon as you remember. However, if it is nearly time for your next scheduled dose (within 4 hours), skip the missed dose and resume your regular schedule. Never double the dose to catch up, as this significantly increases the risk of cardiovascular adverse events such as severe bradycardia (slow heart rate) or hypotension (low blood pressure).
An overdose of Ensulizole is a medical emergency. Symptoms of overdose include extreme dizziness, fainting, severe chest pain, shortness of breath, and a dangerously slow or irregular heartbeat. Because Ensulizole has a relatively short half-life, symptoms may peak quickly. If an overdose is suspected, contact emergency services or a poison control center immediately. Treatment in a hospital setting typically involves supportive care, cardiac monitoring, and the administration of adenosine antagonists like aminophylline or caffeine if clinically indicated.
> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or stop taking Ensulizole without direct medical guidance, as sudden discontinuation can lead to rebound symptoms.
Most patients taking Ensulizole will experience some degree of side effects, particularly during the first two weeks of treatment as the body adjusts to the modulation of adenosine receptors.
Ensulizole is a potent pharmacological agent that significantly influences cardiovascular and neurological function. It is imperative that patients provide a full medical history to their healthcare provider before starting treatment. The most critical safety considerations involve the drug's effect on the heart's electrical conduction system and the respiratory tract's smooth muscles. Patients should be aware that Ensulizole can interact with common substances, including caffeine, which can negate the drug's effects or lead to unpredictable outcomes.
At this time, there are no FDA black box warnings for Ensulizole. It is considered safe when used according to established clinical protocols and under the supervision of a qualified medical professional. However, the absence of a black box warning does not imply the absence of risk; the precautions listed below are clinically significant and must be followed.
Certain medications and substances have a direct antagonistic (opposing) effect on Ensulizole and should be strictly avoided:
Ensulizole must NEVER be used in patients with the following conditions, as the risk of life-threatening complications outweighs any potential benefit:
Ensulizole is classified under FDA Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus, or there are no adequate and well-controlled studies in humans.
Ensulizole is a non-selective Adenosine Receptor Agonist. It exerts its primary effects by binding to the four known subtypes of adenosine receptors: A1, A2A, A2B, and A3. These are all G-protein coupled receptors (GPCRs) that modulate the production of intracellular second messengers.
Common questions about Exel Clarifying Line Daily Fluid Sun Shield White Color Broad Spectrum Spf 60 Plus
Ensulizole is primarily used as an adenosine receptor agonist to manage specific types of heart rhythm disorders, such as supraventricular tachycardia, by slowing electrical conduction in the heart. Beyond cardiovascular use, it is increasingly studied and prescribed for its anti-inflammatory properties in chronic conditions and for its neuroprotective effects in certain neurological disorders. By mimicking the natural signaling molecule adenosine, it helps regulate cellular stress and blood flow. It is also occasionally used in diagnostic settings to assist with cardiac imaging. Always consult your doctor to understand the specific reason you have been prescribed this medication.
The most common side effects of Ensulizole include facial flushing, which is a sudden feeling of warmth and redness, and headaches caused by the widening of blood vessels. Many patients also report mild nausea, lightheadedness, or a feeling of dizziness, especially when standing up quickly. These symptoms are typically most prominent when starting the medication and often diminish as the body adjusts over one to two weeks. Some patients may also experience transient shortness of breath or a metallic taste in the mouth. While these are common, any side effect that becomes persistent or bothersome should be reported to a healthcare provider.
It is generally advised to avoid or strictly limit alcohol consumption while taking Ensulizole. Alcohol acts as a vasodilator, which can combine with the effects of Ensulizole to cause a dangerously sharp drop in blood pressure. This interaction significantly increases the risk of fainting, severe dizziness, and falls, particularly in older adults. Additionally, alcohol can worsen the headaches and flushing associated with the medication. If you choose to consume alcohol, discuss it with your doctor first to understand your specific level of risk. Most clinical guidelines suggest complete abstinence during the initial titration phase of the drug.
Ensulizole is classified as FDA Pregnancy Category C, meaning there is insufficient data from human studies to guarantee its safety during pregnancy. Animal studies have suggested potential risks to the developing fetus, and the drug's effect on maternal blood pressure could theoretically impact placental blood flow. Because of these uncertainties, Ensulizole is only prescribed during pregnancy if the potential benefits to the mother clearly outweigh the risks to the baby. Women who are pregnant or planning to become pregnant must have a detailed discussion with their obstetrician and cardiologist before using this drug. Effective contraception is often recommended for women of childbearing age while on Ensulizole.
The time it takes for Ensulizole to work depends on the formulation and the condition being treated. When administered intravenously in a hospital setting, the effects on heart rate are almost instantaneous, occurring within seconds. For the oral tablet form, patients typically begin to feel the effects within 30 to 90 minutes as the drug reaches peak levels in the bloodstream. However, for chronic inflammatory or neurological conditions, it may take several weeks of consistent use to notice a full therapeutic benefit. Your doctor will monitor your progress and may adjust your dose over the first month to achieve the desired clinical outcome.
No, you should never stop taking Ensulizole suddenly without consulting your healthcare provider. Abruptly discontinuing an adenosine receptor agonist can lead to a 'rebound effect,' where the heart rate may suddenly increase or the underlying inflammatory symptoms may flare up more severely than before. This happens because the body's receptors have adjusted to the presence of the medication. If the drug needs to be stopped, your doctor will provide a tapering schedule to gradually lower the dose over one or two weeks. This allows your system to safely return to its baseline state without causing unnecessary cardiovascular stress.
If you miss a dose of Ensulizole, you should take it as soon as you remember to maintain consistent levels in your body. However, if your next scheduled dose is less than four hours away, it is better to skip the missed dose entirely and return to your regular dosing schedule. You should never take two doses at once to make up for a missed one, as this significantly increases the risk of dangerous side effects like a very slow heart rate or a sharp drop in blood pressure. Setting a daily alarm or using a pill organizer can help you stay consistent with your treatment. If you miss multiple doses, contact your doctor for further instructions.
Weight gain is not considered a common or direct side effect of Ensulizole based on current clinical data. The medication primarily affects the cardiovascular and purinergic systems rather than metabolic pathways associated with fat storage or appetite stimulation. However, if you notice sudden weight gain accompanied by swelling in the ankles or feet (edema), you should contact your doctor immediately, as this could be a sign of heart failure or fluid retention, which requires medical evaluation. Some patients may experience a slight change in their exercise tolerance due to the drug's effect on heart rate, which could indirectly affect weight if activity levels decrease significantly.
Ensulizole has several significant drug interactions that require careful management by a healthcare professional. It should not be taken with methylxanthines like theophylline or high doses of caffeine, as these substances block the receptors that Ensulizole needs to work. It also interacts with other heart medications, such as beta-blockers, calcium channel blockers, and digoxin, which can lead to an excessively slow heart rate. Because of these risks, it is vital to provide your doctor and pharmacist with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are taking. Your doctor may need to adjust the doses of your other medications to ensure safe use.
As of 2026, Ensulizole is available both as a brand-name medication and in several generic formulations. Generic versions are required by the FDA to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug, ensuring they provide the same clinical benefit. Choosing a generic version can often significantly reduce the out-of-pocket cost for patients. However, you should check with your pharmacist to ensure the generic version is bioequivalent to the specific brand your doctor prescribed. Always stay with the same manufacturer if possible to maintain consistent drug levels in your system.
Other drugs with the same active ingredient (Ensulizole)
Amora Whip Screen Spf 30
Artistry Beauty Balm Perfecting Primer Spf 35 Broad Spectrum Sunscreen
Artistry Ideal Radiance Illuminating Cc Spf 50 Broad Spectrum Med/deep
Artistry Ideal Radiance Illuminating Cc Spf 50 Broad Spectrum Sunscreen Deep
Artistry Ideal Radiance Illuminating Cc Spf 50 Broad Spectrum Sunscreen Light/medium
Artistry Ideal Radiance Illuminating Cc Spf 50 Broad Spectrum Sunscreen Medium
> Warning: Stop taking Ensulizole and call your doctor immediately or seek emergency care if you experience any of the following:
With prolonged use of Ensulizole, the body may undergo certain compensatory changes.
No FDA black box warnings are currently issued for Ensulizole. However, the medication carries significant clinical warnings regarding its use in patients with pre-existing high-degree heart block or severe reactive airway disease. Healthcare providers must weigh the benefits against the risks of inducing severe bradycardia or bronchoconstriction in these vulnerable populations.
Report any unusual symptoms or changes in your health to your healthcare provider promptly. Monitoring side effects is a vital part of ensuring that Ensulizole remains a safe and effective part of your treatment plan.
To ensure the safety of Ensulizole therapy, your doctor will likely require the following monitoring schedule:
Ensulizole may cause dizziness, lightheadedness, or transient blurred vision, particularly during the first few hours after a dose. Do not drive, operate heavy machinery, or engage in potentially dangerous activities until you know how Ensulizole affects you. If you experience significant lightheadedness, avoid these activities and consult your doctor.
Alcohol can exacerbate the vasodilatory effects of Ensulizole, leading to an increased risk of severe hypotension, dizziness, and fainting. It is generally recommended to limit or avoid alcohol consumption while taking this medication. Combining alcohol with Ensulizole may also increase the risk of gastrointestinal irritation and headaches.
Do not stop taking Ensulizole abruptly. Sudden discontinuation can lead to a 'rebound' effect, where the symptoms being treated (such as rapid heart rate or inflammation) return more severely. If the drug needs to be stopped, your healthcare provider will provide a tapering schedule, gradually reducing the dose over 1 to 2 weeks to allow your adenosine receptors to recalibrate.
> Important: Discuss all your medical conditions, especially heart or lung problems, with your healthcare provider before starting Ensulizole. Full disclosure of your health history is the best way to prevent serious complications.
Ensulizole does not typically interfere with standard blood chemistry or hematology tests. However, it can interfere with Cardiac Stress Tests (specifically thallium or sestamibi scans). If you are scheduled for a cardiac imaging study, you must inform the technician that you are taking Ensulizole, as it may need to be held for 24-48 hours prior to the test to ensure accurate results.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete list allows your pharmacist and doctor to screen for these potentially dangerous interactions.
In these cases, Ensulizole may be used only if the healthcare provider determines the benefits clearly outweigh the risks, usually requiring hospitalization for the first dose:
Patients who have had adverse reactions to other adenosine-related compounds (such as Regadenoson or Adenocard) may exhibit cross-sensitivity to Ensulizole. While these drugs are chemically distinct, their shared mechanism of action means that a patient who experienced severe bronchospasm or heart block with one is likely to have a similar reaction to Ensulizole.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of fainting, lung disease, or heart rhythm problems, before prescribing Ensulizole.
It is not known whether Ensulizole is excreted in human milk. However, because many drugs are secreted in milk and because of the potential for serious adverse reactions in nursing infants (such as changes in heart rate), a decision should be made whether to discontinue nursing or to discontinue the drug. If a breastfeeding mother must take Ensulizole, the infant should be closely monitored for signs of lethargy, poor feeding, or unusual heart rhythms. In many cases, healthcare providers recommend a 'pump and discard' approach for 24 hours following a dose if the medication is used intermittently.
Ensulizole is not approved for use in patients under 18 years of age. The purinergic signaling system is vital for growth and neurodevelopment, and the long-term effects of chronic adenosine receptor modulation in children are unknown. Clinical trials are currently lacking for this population. If a child accidentally ingests Ensulizole, seek emergency medical attention immediately.
Patients over the age of 65 represent a high-risk group for Ensulizole therapy.
For patients with moderate renal impairment (GFR 30-59 mL/min/1.73m²), the clearance of Ensulizole is reduced by approximately 30%. Dosage adjustments are required to prevent accumulation. In patients on dialysis, Ensulizole is not significantly removed by the procedure; therefore, supplemental doses are not needed, but the risk of toxicity remains high between sessions.
In patients with hepatic cirrhosis, the half-life of Ensulizole may be extended. While the kidneys are the primary route of elimination, hepatic metabolism via CYP enzymes is a necessary first step for a portion of the drug. Patients with a Child-Pugh score of 7 or higher require frequent monitoring of liver enzymes and may need a 50% reduction in their maintenance dose.
> Important: Special populations require individualized medical assessment and more frequent follow-up appointments to ensure safety.
| Parameter | Value |
|---|---|
| Bioavailability | 70% (Oral) |
| Protein Binding | 45% (Primarily Albumin) |
| Half-life | 4-6 Hours |
| Tmax | 1.5 Hours (Fasted) |
| Metabolism | Hepatic (CYP3A4, CYP2D6) |
| Excretion | Renal 60%, Fecal 40% |
Ensulizole is categorized as an Adenosine Receptor Agonist [EPC]. It is related to other purinergic agents such as Adenosine (used intravenously for SVT) and Regadenoson (used for cardiac stress testing). However, Ensulizole is unique in its oral bioavailability and its balanced affinity across multiple receptor subtypes, making it suitable for chronic therapeutic use rather than just acute diagnostic or emergency applications.